1. Pharmacy costs are getting harder to control
41% of employers say managing total prescription drug spend across medical and pharmacy benefits is a growing challenge.
2. Specialty drugs dominate attention, but they’re not the whole problem
High‑cost specialty medications and GLP‑1s drive cost concerns, and employers are exploring different options.
|
Part of Plan |
Interested in Adding |
Biosimilar first strategy that excludes the reference drug
|
35% |
21% |
| Exclusion list of high cost/low value clinical value drugs |
25% |
20% |
| Low wholesale acquisition cost (WAC) formulary |
20% |
18% |
3. GLP-1 adherence drives value, but support gaps limit impact
Members with ≥80% adherence to GLP-1 therapies achieve better clinical and cost outcomes. However, only 31% of employers covering GLP-1s for weight loss have built in adherence support, representing a meaningful missed opportunity to improve both outcomes and cost effectiveness.
4. Lifestyle programs and network controls are underutilized levers
51% of employers covering GLP-1s for weight loss offer lifestyle modification programs, yet only 26% mandate participation for GLP-1 coverage. Additionally, just 18% restrict prescriber or pharmacy network options.
5. Transparency remains a concern
22% of employers have a transparent pharmacy benefit manager (PBM) pricing model, such as pass-through, acquisition or cost plus. Assessing and improving visibility enables better decision-making, even before major program design changes. Without greater pricing transparency, employers have limited ability to understand true drug costs, evaluate vendor performance or effectively control overall pharmacy spend.